Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCS1477 in Advanced Solid/Metastatic Tumours
NCT03568656Phase 2Completed
- Sponsor
- CellCentric
- Start
- Jul 2018
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of inobrodib in metastatic castration-resistant prostate cancer (mCRPC), breast cancer, non-small cell lung cancer (NSCLC), solid tumor (advanced stage), sponsored by CellCentric. Started Jul 2018; status: completed.
02
Drugs
inobrodib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)breast cancernon-small cell lung cancer (NSCLC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03568656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568656.